GLP-1 S Research Guide: GLP-1 Agonism: Mechanism & Research Overview

GLP-1 S is a long-acting GLP-1 receptor agonist developed by Novo Nordisk. Structurally, it is a modified native GLP-1 with an Aib substitution at position 8 (DPP-4 resistance), an Arg substitution at position 34, and a C18 fatty diacid chain attached via a spacer at lysine 26 — the modification responsible for its extended half-life.

It is one of the most extensively studied incretin-class molecules in published clinical research literature.

GLP-1 receptor activation drives glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and signals satiety via hypothalamic GLP-1 receptors.

Unlike short-acting GLP-1 analogues, the albumin-bound depot produces sustained receptor occupancy across the full weekly interval.

The STEP program (Wilding et al., NEJM 2021) reported mean weight reductions of ~15% from baseline at 68 weeks in adults with obesity. The SUSTAIN program established glycemic efficacy in type 2 diabetes research populations.

Research-grade GLP-1 S should be ≥99% pure by HPLC with mass spectrometry confirmation. Redline Bio GLP-1 S ships with batch documentation; independent COAs are published on the lab reports page as testing returns.

GLP-1 S is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable regulations.